Association of elevated plasma B-type natriuretic peptide levels with paroxysmal atrial fibrillation in patients with nonobstructive hypertrophic cardiomyopathy

Hiroko Matsuura, Takashi Murakami, Kazuyoshi Hina, Keizo Yamamoto, Hiroshi Kawamura, Taiji Sogo, Ryouko Shinohata, Shinichi Usui, Yoshifumi Ninomiya, Shozo Kusachi

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Objectives: To investigate the relationship between the plasma B-type natriuretic peptide (BNP) level and the occurrence of atrial fibrillation (AF) in nonobstructive hypertrophic cardiomyopathy (HCM) patients. Methods: Patients (n = 97) were classified into chronic AF (CAF; n = 14), paroxysmal AF (PAF; n = 18) and normal sinus rhythm (NSR; n = 65) groups. The plasma BNP values were analyzed with logarithmic transformation. Results: The PAF group showed significantly higher plasma BNP levels than the NSR group [mean (range; - l SD and + 1 SD); 248.3 (143.5, 429.5) vs. 78.2 (27.9, 218.8 ng/L), p <0.0001]. The CAF group also showed significantly higher plasma BNP levels than the NSR group [291.1 (161.4, 524.8 ng/L), p <0.0001]. Multivariate analysis with other clinical factors selected association of PAF as one of the factors that increased the plasma BNP level. Conclusions: The present study indicated that plasma BNP level is clinically useful for identification of nonobstructive HCM patients who have a risk of PAF.

Original languageEnglish
Pages (from-to)134-139
Number of pages6
JournalClinical Biochemistry
Volume41
Issue number3
DOIs
Publication statusPublished - Feb 2008

Fingerprint

Brain Natriuretic Peptide
Hypertrophic Cardiomyopathy
Atrial Fibrillation
Plasmas
Multivariate Analysis

Keywords

  • Cardiomyopathy
  • Clinical study
  • Enzyme immunoassay
  • Peptide
  • Sensitivity and specificity
  • Tachyarrhythmia

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Association of elevated plasma B-type natriuretic peptide levels with paroxysmal atrial fibrillation in patients with nonobstructive hypertrophic cardiomyopathy. / Matsuura, Hiroko; Murakami, Takashi; Hina, Kazuyoshi; Yamamoto, Keizo; Kawamura, Hiroshi; Sogo, Taiji; Shinohata, Ryouko; Usui, Shinichi; Ninomiya, Yoshifumi; Kusachi, Shozo.

In: Clinical Biochemistry, Vol. 41, No. 3, 02.2008, p. 134-139.

Research output: Contribution to journalArticle

Matsuura, Hiroko ; Murakami, Takashi ; Hina, Kazuyoshi ; Yamamoto, Keizo ; Kawamura, Hiroshi ; Sogo, Taiji ; Shinohata, Ryouko ; Usui, Shinichi ; Ninomiya, Yoshifumi ; Kusachi, Shozo. / Association of elevated plasma B-type natriuretic peptide levels with paroxysmal atrial fibrillation in patients with nonobstructive hypertrophic cardiomyopathy. In: Clinical Biochemistry. 2008 ; Vol. 41, No. 3. pp. 134-139.
@article{baaa5a1c8c96481f9fdee493119aec17,
title = "Association of elevated plasma B-type natriuretic peptide levels with paroxysmal atrial fibrillation in patients with nonobstructive hypertrophic cardiomyopathy",
abstract = "Objectives: To investigate the relationship between the plasma B-type natriuretic peptide (BNP) level and the occurrence of atrial fibrillation (AF) in nonobstructive hypertrophic cardiomyopathy (HCM) patients. Methods: Patients (n = 97) were classified into chronic AF (CAF; n = 14), paroxysmal AF (PAF; n = 18) and normal sinus rhythm (NSR; n = 65) groups. The plasma BNP values were analyzed with logarithmic transformation. Results: The PAF group showed significantly higher plasma BNP levels than the NSR group [mean (range; - l SD and + 1 SD); 248.3 (143.5, 429.5) vs. 78.2 (27.9, 218.8 ng/L), p <0.0001]. The CAF group also showed significantly higher plasma BNP levels than the NSR group [291.1 (161.4, 524.8 ng/L), p <0.0001]. Multivariate analysis with other clinical factors selected association of PAF as one of the factors that increased the plasma BNP level. Conclusions: The present study indicated that plasma BNP level is clinically useful for identification of nonobstructive HCM patients who have a risk of PAF.",
keywords = "Cardiomyopathy, Clinical study, Enzyme immunoassay, Peptide, Sensitivity and specificity, Tachyarrhythmia",
author = "Hiroko Matsuura and Takashi Murakami and Kazuyoshi Hina and Keizo Yamamoto and Hiroshi Kawamura and Taiji Sogo and Ryouko Shinohata and Shinichi Usui and Yoshifumi Ninomiya and Shozo Kusachi",
year = "2008",
month = "2",
doi = "10.1016/j.clinbiochem.2007.10.015",
language = "English",
volume = "41",
pages = "134--139",
journal = "Clinical Biochemistry",
issn = "0009-9120",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Association of elevated plasma B-type natriuretic peptide levels with paroxysmal atrial fibrillation in patients with nonobstructive hypertrophic cardiomyopathy

AU - Matsuura, Hiroko

AU - Murakami, Takashi

AU - Hina, Kazuyoshi

AU - Yamamoto, Keizo

AU - Kawamura, Hiroshi

AU - Sogo, Taiji

AU - Shinohata, Ryouko

AU - Usui, Shinichi

AU - Ninomiya, Yoshifumi

AU - Kusachi, Shozo

PY - 2008/2

Y1 - 2008/2

N2 - Objectives: To investigate the relationship between the plasma B-type natriuretic peptide (BNP) level and the occurrence of atrial fibrillation (AF) in nonobstructive hypertrophic cardiomyopathy (HCM) patients. Methods: Patients (n = 97) were classified into chronic AF (CAF; n = 14), paroxysmal AF (PAF; n = 18) and normal sinus rhythm (NSR; n = 65) groups. The plasma BNP values were analyzed with logarithmic transformation. Results: The PAF group showed significantly higher plasma BNP levels than the NSR group [mean (range; - l SD and + 1 SD); 248.3 (143.5, 429.5) vs. 78.2 (27.9, 218.8 ng/L), p <0.0001]. The CAF group also showed significantly higher plasma BNP levels than the NSR group [291.1 (161.4, 524.8 ng/L), p <0.0001]. Multivariate analysis with other clinical factors selected association of PAF as one of the factors that increased the plasma BNP level. Conclusions: The present study indicated that plasma BNP level is clinically useful for identification of nonobstructive HCM patients who have a risk of PAF.

AB - Objectives: To investigate the relationship between the plasma B-type natriuretic peptide (BNP) level and the occurrence of atrial fibrillation (AF) in nonobstructive hypertrophic cardiomyopathy (HCM) patients. Methods: Patients (n = 97) were classified into chronic AF (CAF; n = 14), paroxysmal AF (PAF; n = 18) and normal sinus rhythm (NSR; n = 65) groups. The plasma BNP values were analyzed with logarithmic transformation. Results: The PAF group showed significantly higher plasma BNP levels than the NSR group [mean (range; - l SD and + 1 SD); 248.3 (143.5, 429.5) vs. 78.2 (27.9, 218.8 ng/L), p <0.0001]. The CAF group also showed significantly higher plasma BNP levels than the NSR group [291.1 (161.4, 524.8 ng/L), p <0.0001]. Multivariate analysis with other clinical factors selected association of PAF as one of the factors that increased the plasma BNP level. Conclusions: The present study indicated that plasma BNP level is clinically useful for identification of nonobstructive HCM patients who have a risk of PAF.

KW - Cardiomyopathy

KW - Clinical study

KW - Enzyme immunoassay

KW - Peptide

KW - Sensitivity and specificity

KW - Tachyarrhythmia

UR - http://www.scopus.com/inward/record.url?scp=38849146408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38849146408&partnerID=8YFLogxK

U2 - 10.1016/j.clinbiochem.2007.10.015

DO - 10.1016/j.clinbiochem.2007.10.015

M3 - Article

C2 - 18039472

AN - SCOPUS:38849146408

VL - 41

SP - 134

EP - 139

JO - Clinical Biochemistry

JF - Clinical Biochemistry

SN - 0009-9120

IS - 3

ER -